# PEG-MGF

> A pegylated form of Mechano Growth Factor (MGF) designed for a longer half-life than the native IGF-1Ec splice peptide.

- Also known as: Pegylated MGF, PEG Mechano Growth Factor, PEG-IGF-1Ec
- Class: Growth Hormone
- FDA approved: No
- Canonical page: https://americanpeptide.com/catalog/peg-mgf

## Overview

PEG-MGF is Mechano Growth Factor — the IGF-1Ec splice variant released by mechanically loaded muscle — with a polyethylene-glycol (PEG) chain attached to extend its short half-life. Native MGF is cleared very quickly, so pegylation is used in research settings to keep the peptide in circulation long enough to study its proposed role in activating muscle satellite cells and local repair. It is a research compound, profiled here as the long-acting form of MGF; see the MGF entry for the underlying biology. It is not FDA-approved.

MGF is the locally acting splice variant of IGF-1 that muscle produces in response to mechanical load; its distinctive E-domain is thought to activate the satellite cells that repair and grow muscle. Its practical problem as a research tool is speed of clearance — native MGF disappears from circulation almost immediately.

Pegylation is the standard fix: attaching a PEG chain shields the peptide and slows its removal, giving a longer-lived version for study. PEG-MGF is that long-acting form. The biology it is probing is MGF’s, and the evidence is preclinical; it is not FDA-approved. This page is a research and educational reference.

## Mechanism

Same MGF signal — satellite-cell activation and local muscle repair via the E-domain of the IGF-1Ec splice variant — with a PEG chain that slows renal clearance and proteolysis to extend circulating half-life.

## Research areas

Studied in: Muscle repair and hypertrophy (preclinical), Satellite-cell activation, Peptide half-life engineering.

## Key research

- Long-acting MGF — pegylation extends the very short half-life of native MGF for research use.
- Satellite-cell signal — carries the same IGF-1Ec E-domain activity proposed to drive local muscle repair.
- Half-life engineering — a textbook use of PEG to stabilize a rapidly cleared peptide.
- Preclinical — not FDA-approved; see the MGF entry for the base biology.

## Storage, handling & synthesis

**Storage.** Store lyophilized, frozen, and protected from light; keep reconstituted peptide cold and use within a short window. The PEG conjugate is sensitive to the same heat and agitation stresses as the underlying peptide.

**Handling.** Reconstitute gently without vortexing. Identity work should characterize the PEG conjugate — attachment site and PEG size — not just the MGF peptide backbone.

**Synthesis.** The MGF backbone is a ~24-residue peptide made by solid-phase synthesis, but the hard, poorly-standardized step is the PEG conjugation — the attachment site and PEG size determine the product, and “PEG-MGF” materials vary widely in how (and whether) the PEG is actually coupled. Identity work has to characterize the conjugate, not just the peptide, which is rarely disclosed on product pages.

## FAQs

### What is PEG-MGF?

Mechano Growth Factor (the IGF-1Ec splice peptide) with a PEG chain attached to extend its otherwise very short half-life for research use.

### Why pegylate MGF?

Native MGF is cleared almost immediately; the PEG chain slows clearance and proteolysis so the peptide stays in circulation long enough to study.

### How is it different from MGF?

Same signaling peptide and proposed biology — the difference is the pegylation that makes PEG-MGF longer-acting. See the MGF entry for the base science.

### Is it approved?

No — it is a research compound, not FDA-approved. This page is a research and educational reference.

## Latest research

Recent trials and publications mentioning PEG-MGF, pulled automatically from ClinicalTrials.gov and PubMed (unfiltered search results, refreshed daily).

### Recent trials

- [Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies](https://clinicaltrials.gov/study/NCT07177352) — RECRUITING · PHASE3 · NCT07177352
- [A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease](https://clinicaltrials.gov/study/NCT07170150) — ACTIVE_NOT_RECRUITING · PHASE3 · NCT07170150
- [A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)](https://clinicaltrials.gov/study/NCT04777396) — COMPLETED · PHASE3 · NCT04777396
- [A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)](https://clinicaltrials.gov/study/NCT04777409) — COMPLETED · PHASE3 · NCT04777409
- [Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat SGA Children With Short Stature](https://clinicaltrials.gov/study/NCT02375620) — ACTIVE_NOT_RECRUITING · PHASE2 · NCT02375620
- [Lipoprotein(a) in Patients With Cardiovascular Disease (CVD)](https://clinicaltrials.gov/study/NCT03887520) — COMPLETED · NA · NCT03887520

---

Source: AmericanPeptide.com — https://americanpeptide.com/catalog/peg-mgf
Data license: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Attribution: AmericanPeptide.com.
Research reference only — computational and educational content, not medical advice.